Evidence map›Paper›PMID 39771599›Full record

ArticlePharmaceutics2024

Early-Stage IM Treatment with the Host-Derived Immunostimulant CPDI-02 Increases Curative Protection of Healthy Outbred Mice Against Subcutaneous Infection with Community-Acquired Methicillin-Resistant

Jason P Stewart, Caleb M Sandall, Jacob E Parriott, Stephen M Curran, Russell J McCulloh, Donald R Ronning, Joy A Phillips, Robin Schroeder, Christy Neel, Kelly F Lechtenberg and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jason P StewartDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Caleb M SandallDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Jacob E ParriottDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Stephen M CurranDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Russell J McCullohDepartment of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Donald R RonningDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Joy A PhillipsBiology Department, San Diego State University, San Diego, CA 92182, USA.
Robin SchroederMidwest Veterinary Services, Inc., Oakland, NE 68045, USA.
Christy NeelMidwest Veterinary Services, Inc., Oakland, NE 68045, USA.
Kelly F LechtenbergMidwest Veterinary Services, Inc., Oakland, NE 68045, USA.
Samuel M CohenDepartment of Pathology, Microbiology, and Immunology and the Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-5047-0962
Yazen AlnoutiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Sohel DariaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
D David SmithDepartment of Biomedical Sciences, Creighton University, Omaha, NE 68178, USA.
Joseph A VetroDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-2446-9797

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Heather Colleen Jensen-Smith · 2012 to 2026
$59.2M
Understanding the progression of hearing loss in an endolymphatic hydrops modelP20GM139762 · NIGMS · CREIGHTON UNIVERSITY · PI Hui Hong · 2021 to 2026
$16.1M
The Nebraska Pediatric Clinic Trials UnitUG1OD024953 · OD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Bradford A Brabec, Ellen Kerns · 2016 to 2026
$4.4M
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMVR01AI121050 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VETRO, JOSEPH ANTHONEY · 2016 to 2020
$1.9M
Host-Directed Immunotherapy: A "One Health" ApproachR01AI125137 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VETRO, JOSEPH ANTHONEY · 2016 to 2020
$1.9M
NIAID NIH HHS R01 AI121050NIAID NIH HHS R01 AI125137NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P20 GM139762NIH HHS UG1 OD024953NIH/NIAID 1R01AI121050NIH/NIAID 5R01AI125137NIH/NIGMS GM103427NIH/NIGMS GM139762NIH Office of the Director UG1OD024953Weitz Family Foundation n/a
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ABRadministration routeAMRantibiotic resistanceantibiotic-resistant bacteriaantimicrobial resistancecomplement peptide-derived immunostimulantCPDI-02 dosingCPDI-02 toxicitydrug-resistant bacteriaEP67host-directed therapyMDRmultidrug resistance

Identifiers

PMID39771599
PMCPMC11677424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.